Atlas Trials

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

Clinical trial NCT01984697 · COMPLETED

Trial details

NCT number
NCT01984697
Sponsor
Merck Sharp & Dohme LLC
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Human Papillomavirus Infection
Start date
2013-12-12
Primary completion
2015-06-19
Enrollment
1518

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.